| KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON |
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kronos Bio, Inc. (NasdaqGS: KRON) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Kronos will receive $0.57 in cash per share plus one non-tradeable contingent value right. KSF is seeking to determine whether this consideration and the process that le. |
businesswire.com |
2025-05-04 16:11:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRON |
NEW YORK , May 1, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Kronos Bio, Inc. (NASDAQ: KRON ), relating to the proposed merger with Concentra Biosciences, LLC. |
prnewswire.com |
2025-05-01 21:30:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Kronos (Nasdaq: KRON) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Kronos will receive only $0.57 per share, plus one contingent value right, which represent. |
businesswire.com |
2025-05-01 13:54:00 |
Czytaj oryginał (ang.) |
| KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Kronos Bio, Inc. (NASDAQ: KRON) to Concentra Biosciences, LLC for $0.57 in cash per share plus one non-tradeable contingent value right is fair to Kronos shareholders. Halper Sadeh encourages Kronos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. |
businesswire.com |
2025-05-01 13:34:00 |
Czytaj oryginał (ang.) |
| Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right |
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock (“Kronos Bio Common Stock”), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-9558 and KB-7898 that occurs within 2 years following closing; (ii) 100% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-0742, lanraplenib and entospletinib that occurs prior to closing; (iii) 100% of cost savings realized prior to closing; (iv) 80% of cost savings realized between the merger closing date and the second (2nd) anniversary of the merger closing date; and (v) 50% of cost savings realized between the second (2nd) anniversary of the merger closing date and the third (3rd) anniversary of the merger closing date, each pursuant to the contingent value rights agreement (the “CVR Agreement”). |
globenewswire.com |
2025-05-01 12:30:00 |
Czytaj oryginał (ang.) |
| Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results |
SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. |
globenewswire.com |
2025-03-18 18:01:00 |
Czytaj oryginał (ang.) |
| Kronos Bio Announces CEO Transition and Reduction in Force |
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D. |
globenewswire.com |
2024-11-27 09:30:00 |
Czytaj oryginał (ang.) |
| Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 |
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures – |
globenewswire.com |
2024-11-14 18:02:00 |
Czytaj oryginał (ang.) |
| Kronos Bio downgraded to Neutral from Overweight at Piper Sandler |
Piper Sandler analyst Edward Tenthoff downgraded Kronos Bio to Neutral from Overweight with a price target of $1, down from $6. |
https://thefly.com |
2024-11-13 20:36:03 |
Czytaj oryginał (ang.) |
| Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates |
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.54 per share a year ago. |
zacks.com |
2024-11-13 20:31:14 |
Czytaj oryginał (ang.) |
| Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors |
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – – Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – |
globenewswire.com |
2024-10-23 12:55:00 |
Czytaj oryginał (ang.) |
| Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors |
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects – |
globenewswire.com |
2024-10-09 12:55:00 |
Czytaj oryginał (ang.) |
| Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease |
– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor regulatory networks – |
globenewswire.com |
2024-10-07 12:55:00 |
Czytaj oryginał (ang.) |
| Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy |
– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases – |
globenewswire.com |
2024-09-25 12:55:00 |
Czytaj oryginał (ang.) |
| Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer |
– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance – |
globenewswire.com |
2024-09-23 12:55:00 |
Czytaj oryginał (ang.) |
| After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) |
The heavy selling pressure might have exhausted for Kronos Bio (KRON) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-09-10 14:36:05 |
Czytaj oryginał (ang.) |
| Kronos Bio Announces Participation in Medical and Investor Conferences in September |
SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the following upcoming conferences: |
globenewswire.com |
2024-09-03 12:55:00 |
Czytaj oryginał (ang.) |
| After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) |
Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-08-22 14:36:08 |
Czytaj oryginał (ang.) |
| Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy? |
Kronos Bio (KRON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-08-06 15:05:41 |
Czytaj oryginał (ang.) |
| Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer |
— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass. |
globenewswire.com |
2024-07-23 20:15:00 |
Czytaj oryginał (ang.) |
| Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting |
— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — |
globenewswire.com |
2024-05-23 21:15:00 |
Czytaj oryginał (ang.) |
| Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events |
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events. Norbert Bischofberger, Ph.D., president and chief executive officer, will represent the company at these events. |
globenewswire.com |
2024-05-22 20:30:00 |
Czytaj oryginał (ang.) |
| Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer |
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions. |
globenewswire.com |
2024-05-21 12:15:00 |
Czytaj oryginał (ang.) |
| Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround |
Kronos Bio (KRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-05-16 14:36:05 |
Czytaj oryginał (ang.) |
| Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates |
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.46 per share a year ago. |
zacks.com |
2024-05-09 22:46:12 |
Czytaj oryginał (ang.) |
| Kronos Bio Reports First-Quarter 2024 Financial Results |
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 — — KB-9558 remains on track with IND-enabling studies expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass. |
globenewswire.com |
2024-05-09 20:05:00 |
Czytaj oryginał (ang.) |